Uncategorized Archives - Page 5 of 157

TuesdayApr 28, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Deploying AI for Non-Invasive Intoxication Detection

Voice Analytics and AI to Transform Drug and Alcohol Testing Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising. MindBio Therapeutics is developing AI-driven voice analysis technology to detect drug and alcohol impairment without relying on invasive and time-consuming breath, saliva, or laboratory testing. The company’s platform analyzes more than 140 acoustic markers and is trained on over 50 million data points to estimate intoxication levels from short voice samples. The new technology is seen applicable to both workplace and non-workplace settings, with the global alcohol and drug testing devices market projected to grow from…

TuesdayApr 28, 2026 9:00 am

The Evidence-Interrogation Play: How Oncotelic Therapeutics Inc.’s (OTLC) PDAOAI Platform Fits Pharma’s Broader AI Transformation

Oncotelic’s PDAOAI platform indexes 125,000+ PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the evidence for testable, auditable hypotheses rather than rely on black-box predictions. Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations. The hypothesis-first approach addresses a core challenge in biotech research: reducing training-set bias and building transparent, reproducible chains from question to evidence to hypothesis. Pharmaceutical research and manufacturing are undergoing a structural transition. Regulatory agencies are raising expectations around data integrity and traceability, while the industry is shifting from…

MondayApr 27, 2026 9:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing AI Solutions for Cardiovascular Disease Detection and Management

The scale and impact of cardiovascular disease underscore why innovation in this area is so critical. Advances in genomics and epigenetics are making it possible to better understand how genetic predisposition and environmental influences interact to drive disease progression. By utilizing a simple blood test, Cardio Diagnostics is lowering barriers to advanced cardiovascular testing. Cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (“AI”) and multi-omic…

FridayApr 24, 2026 11:00 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health

At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health. The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk. CDIO’s focus on accessibility and scalability is also notable. Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary…

MondayApr 20, 2026 10:30 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Broadens AI Intoxication Detection Platform with Launch of Intox Collect(TM)

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The Intox Collect(TM) technology enhances the company’s ability to collect and analyze voice and facial recognition data tied to drug and alcohol impairment. MindBio says the platform broadens detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants. The company’s AI model currently uses more than 50 million data points, with management expecting that figure to increase further. MindBio is developing Edge AI kiosk hardware for enterprise deployment, with prototype testing expected in the second quarter of 2026. Target industries include mining, aviation,…

FridayApr 17, 2026 12:10 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease. SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug…

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

ThursdayApr 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting. In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma. Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging clinical update from its…

ThursdayApr 16, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform The collaboration integrates AI-driven compliance systems with advanced robotics for pharmaceutical manufacturing automation This pivot underscores a broader strategy: extending Oncotelic’s AI capabilities beyond therapeutics into scalable, high-value industrial applications Oncotelic Therapeutics (OTCQB: OTLC) is signaling a significant strategic evolution, moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced…

WednesdayApr 15, 2026 9:45 am

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it. However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients. Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System. Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Deploying AI for Non-Invasive Intoxication Detection

The Evidence-Interrogation Play: How Oncotelic Therapeutics Inc.’s (OTLC) PDAOAI Platform Fits Pharma’s Broader AI Transformation

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing AI Solutions for Cardiovascular Disease Detection and Management

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) AI Platform Brings Precision to Heart Health

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Broadens AI Intoxication Detection Platform with Launch of Intox Collect(TM)

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search